References
- EPSTEIN AE, HALLSTROM AP, ROGERS WJ, LIEBSON PR,SEALS AA, ANDERSON JL, COHEN JD, CAPONE RJ, WYSE DG: Mortality following ventricular arrhythmia sup-pression by encainide, flecainide, and morizicine after myocardial infarction. The original design concept of the cardiac arrhythmia suppression trial (CAST). JAMA (1993) 270(20): 2451–2455.
- TATLA DS, DAVID BC, MALLOY KJ, MOOREHEAD TJ: Invitro electrophysiology of NE-10064, a novel and highly selective Class III anti-arrhythmic agent. FASEBJ. (1993) 7(3): A615.
- BROOKS RR, CARPENTER JF, MAYNARD AE, DECKER GE:Efficacy of a novel Class III anti -arrhythmic agent NE-10064 against ischaemiaireperfusion arrhythmia in rats. FASEBJ, (1993) 7(3)A557.
- DREXLER AP, MICKLAS JM, BROOKS RR: Effects of intra-venously administered NE-10064 on programmed elec-trical stimulations (PES)-induced ventricular arrhythmias in anaesthetised infarcted dogs. FASEB J. (1993) 7(3)A558.
- MILLFR ICE, CARPENTER JF, BROOKS RR: ft-Adrenergiceffects of the Class M anti-arrhythmic agent NE-10064 In the isolated perfused guinea-pig heart. FASEBJ. (1993) 7(3):A620.
- PONG SF, KINNEY CM, MOOREHEAD TJ: Binding profileof NE-10064, a novel Class m antiarrhythmie agent, to rat brain receptors. FASEBJ. (1993) 7(3):A2748.
- BUSCH AE, MALLOY KJ, VARNUM MD, ADELMAN JP,NORTH RA, MAYLIE J: A slowly-activating potassium current Ix is the target for the Class HI anti-arrhythmic drug NE-10064. Circulation (1993) 88(4):A1233. Although the potency of the compound described in this abstract may seem weak, NE-10064 represents the first compound claimed to block the slowly activating delayed rectifier potassium current.
- BERGER F, BORCHARD U, HAFNER D, KAMMER T, WEIS T: Inhibition of the potassium outward currents and pace-maker current in sheep cardiac Purkinje fibres by the verapamil derivative YS 035. Naunyn-Scbmiedeberg's Arch. Pharrnacol. (1991) 344, 653–661.
- SCHOLZ W, ALBUS U, LANG HJ, LINZ W, MARTORANA PA,ENGLERT HC, SCH6LKENS BA: Hoe 694, a new Na±/H+ exchange inhibitor and its effects in cardiac isehamnia Br. J. Pharmacol. (1993) 109:562-568. First report of a selective inhibitor of the Na'ill* exchange
- YASUTAKE M, IBUKI C, HEARSE DJ, AVKIRAN M: Role of Na+/H+ exchange in reperfusion arrhythmogenesis. Eur. Heart J. (1993) 14, Suppl: 86.
- DU TOIT EF, OPIE LH: Neill* exchange inhibition during either the ischaemic or the reperfusion period decreases reperfusion damage in rat heart. Eur. Heartl (1993) 14, Suppl: 95.
- KAUMANN AJ, SANDERS L, BROWN AM, MURRAY KJ, BROWN MJ: A 5-hydroxytryptamine receptor in human atrium. Br. J. Pharmacol. (1990) 100: 879–885.
- MEDHURST AD, KAUMANN AJ: Characterisation of the5-HT4 receptor mediating tachycardia in piglet isolated right atrium. Br. J. Pharmacol. (1993) 110: 1023–1030.
- BERMUDEZ J, FAKE CS, JOINER GF, JOINER ER, KING ED,MINER WD, SANGER GH: 5-Hydroxytryptamine (5-HT3) receptor antagonists. 1. Indazole and indolizine-3-car-boxylic acid derivatives. J. Med. Chem. (1990) 33: 1924–1929.
- PARKER SG, HAMBURGER S, TAYLOR EM, KAUMANN AJ: SB203186, a potent 5-HT4 receptor antagonist, in por-cine sinoatrial node and human and porcine atrium. Br. J. Pharmacol (1993) 108, 68P.
- ZAZA A, MALFAITO G, ROSEN MR: Electrophysiologic effects of Ketanserin on canine Purkinje fibres, ven-tricular myocardium and the intact heart. j Pharmacol. Exp. Tber. (1989) 250: 397–404.
- BOCKAERT J, FOZARD JR, DUMUIS A, CLARICE DE: The5-IIT4 receptor: a place in the sun. Trends Pharmacol. Sci. (1992) 13: 141–145.
- WILLIAMS FM, ROTHAUL AL, KANE ER, PARRATT JR: Anti-arrhythmic and electrophysiological effects of ICS 205-930, an antagonist of 5-hydroxytryptamine at pe-ripheral receptors. J. Cardiovasc. Pharmacol. (1985) 7: 550–555.
- SCHOLTYSIK G: Evidence for inhibition by ICS 205-930and stimulation by BRL 34915 of IC+ conductance in cardiac muscle. Naunyn-Scbmtedeberg's Arch. Pharmacol. (1987) 335: 692–696.
- CHER1CASHIN MI, BORISOVA EYa, KOMAROGV VM, ZUBOV AN, TOLSTIKOV GA: Polymeric effect on anti-ar-rhythmic and anaesthetic activity of aliphatic-aromatic aminoamides. Dokl. Akad. Nauk. SSSR (1990) 313(3) 623–7. CA114(1):191K.
- MORGAN TK JR, SULLIVAN ME: An overview of Class IIIelectrophysiological agents: a new generation of anti-arrhythmic therapy. Progress in Medicinal Chemistry (1992), ELLIS GP, LUSCOMBE DK (Eds.), Elseviers Science Publishers B.V.
- VAUGHAN WILLIAMS EM: Classification of anti-arrhyth-mic actions. In: Antiarrbytbmic drugs (1989), Vaughan Williams EM, Campbell TJ (Eds.), Springer-Verlag, 45–67.
- UPRICHARD ACG, CHI L, LYNCH D, DRISCOLL EM, FRYEJW, LUCCHESI BR: Alinidine reduces the incidence of ischaenic ventricular fibrillation in a conscious canine model, a protective effect antagonized by overdrive atrial pacing. J. Cardiovasc. Pharrnacol. (1989) 14: 475–482,
- BRIL A, FOREST MC, CHEVAL B, LANDAIS L, GOUT B: Effectof zatebradine, a specific bradycardic agent, on ischae-mia-induced arrhythmias in anaesthetised rabbits. Pharmacology: in press.
- SUTTER MC, WANG YX: Recent cardiovascular drugs from Chinese medicinal plants. Cardiovasc. Res. (1993) 27:1891–1901.
Reference to patent literature
- AMERICAN HOME PRODUCTS CORPORATION, US5202346.
- AMERICAN HOME PRODUCTS CORPORATION, US5187189.
- PROCTER & GAMBLE PHARM, W0930460.
- PROCTER & GAMBLE PHARM, W0930461.
- PROCTER & GAMBLE PHARM, W0930464.
- BASF AG, EP–534246–A.
- EGIS GYOGYSZERGYAR, GB2262526–A.
- HOECHST AG, EP–556672–A.
- HOECHST AG, EP–556673–A.
- HOECHST AG, EP–556674–A.
- SMITHKLINE BEECHAM, W09316072,
- SMITHKLINE BEECHAM, W09318036.
- SMITHKLINE BEECHAM, W09303725.
- SMITHKLINE BEECHAM, W09305040.
- SMITHKLINE BEECHAM, W09318027.
- PIERRE FABRE MEDICAMENT, EP–527081–A.
- AH ROBIN & CO, U55190953.
- AH ROBIN & CO, U55244907.
- MITSLTBISHI KASEI CORPORATION, EP-560348–A.
- UNIVERSITY OF BRITISH COLUMBIA, W09319056.
- ZENTRUM FOR CHEMIE DER ARZNEIMITTEL, EP-535256–A.
- STERLING WINTHROP INC, US5183813.
- ADIR ET CO, EP–534859–A.
- STERLING DRUG INC, US5206231.
- CHIN PHARM UNIVERSITY, EP–538844–A.